Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Amicus Therapeutics Q2 Adj. EPS $0.01 Beats $(0.11) Estimate, Sales $154.688M Beat $147.399M Estimate

Author: Benzinga Newsdesk | July 31, 2025 06:06am
Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.11) by 109.09 percent. This is a 83.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $154.688 million which beat the analyst consensus estimate of $147.399 million by 4.94 percent. This is a 22.12 percent increase over sales of $126.669 million the same period last year.

Posted In: FOLD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist